Emphasis on the early diagnosis of antithyroid drug-induced agranulocytosis: retrospective analysis over 16 years at one Chinese center

[21] Ito K(2001)Haematopoietic growth factor in antithyroid-drug-induced agranulocytosis QJM 94 423-428

[22] Nakamura H(2009)Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30mg daily than with 15mg daily Thyroid 19 559-563

[23] Miyauchi A(2011)Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists Thyroid 21 593-646

[24] Miyawaki N(2007)Antithyroid drug-induced agranulocytosis: report of 13 cases Chang Guang Med J 30 242-248

[25] Imagawa J(1993)Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF) Thyroid 3 305-309

[26] Andersen SL(2009)Antithyroid drug-induced agranulocytosis J Chin Med Assoc 72 438-441

[27] Olsen J(2002)Retrospective analysis of 18 cases of antithyroid drug (ATD)-induced agranulocytosis Endocr J 49 29-33

[28] Laurberg P(1991)Agranulocytosis associated with anti-thyroid drug in patients with Graves’ thyrotoxicosis–report of 11 cases Chang Guang Med J 14 168-173

[29] Roeloffzen WW(2007)Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 92 S1-S47

[30] Verhaegh JJ(2011)The American Thyroid Association and American Association of Clinical Endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines: viewpoints from Japan and Korea Thyroid 21 577-580

[21] Ito K(2001)Haematopoietic growth factor in antithyroid-drug-induced agranulocytosis QJM 94 423-428

[22] Nakamura H(2009)Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30mg daily than with 15mg daily Thyroid 19 559-563

[23] Miyauchi A(2011)Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists Thyroid 21 593-646

[24] Miyawaki N(2007)Antithyroid drug-induced agranulocytosis: report of 13 cases Chang Guang Med J 30 242-248

[25] Imagawa J(1993)Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF) Thyroid 3 305-309

[26] Andersen SL(2009)Antithyroid drug-induced agranulocytosis J Chin Med Assoc 72 438-441

[27] Olsen J(2002)Retrospective analysis of 18 cases of antithyroid drug (ATD)-induced agranulocytosis Endocr J 49 29-33

[28] Laurberg P(1991)Agranulocytosis associated with anti-thyroid drug in patients with Graves’ thyrotoxicosis–report of 11 cases Chang Guang Med J 14 168-173

[29] Roeloffzen WW(2007)Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 92 S1-S47

[30] Verhaegh JJ(2011)The American Thyroid Association and American Association of Clinical Endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines: viewpoints from Japan and Korea Thyroid 21 577-580